2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 5, 2010, Pages 1724-1727

  Gerspacher, Marc ^a   Furet, Pascal ^a   Pissot Soldermann, Carole ^a   Gaul, Christoph ^a   Holzer, Philipp ^a   Vangrevelinghe, Eric ^a   Lang, Marc ^a   Erdmann, Dirk ^a   Radimerski, Thomas ^a   Regnier, Catherine H ^a   Chene, Patrick ^a   Pover, Alain De ^a   Hofmann, Francesco ^a   Baffert, Fabienne ^a   Buhl, Thomas ^a   Aichholz, Reiner ^a   Blasco, Francesca ^a   Endres, Ralf ^a   Trappe, Jörg ^a   Drueckes, Peter ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

JAK1; JAK2; JAK2 inhibitor; JAK3; Janus kinase; Kinase inhibitors; Tyk2

Indexed keywords

2 AMINO ARYL 7 ARYL BENZOXAZOLE; JANUS KINASE INHIBITOR; PYRROLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BENZOXAZOLES; JANUS KINASE 2; PROTEIN KINASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 76649112726     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.069     Document Type: Article

References (13)

1. Harpur A.G., Andres A.C., Ziemiecki A., et al. Oncogene 7 (1992) 1347
2. Saharinen P., Vihinen M., and Silvennoinen O. Mol. Biol. Cell. 14 (2003) 1448
3. Yamoka K., Saharinen P., Pesu M., et al. Genome Biol. 5 (2004) 253
4. James C., Ugo V., Le Couedic J.-P., et al. Nature 434 (2005) 1144
5. Levine R.L., Wadleigh M., Cools J., et al. Cancer Cell 7 (2005) 673
6. Valentino L., and Pierre. J. Biochem. Pharmacol. 71 (2006) 713
7. Vainchenker W., and Constaninescu S.N. Am. Soc. Hematol. Educ. Program (2005) 195
8. Tefferi A., Barosi G., Mesa R.A., et al. Blood 108 (2006) 1497
9. Choi H.-S., Wang Z., Richmond W., He X., Yang K., Jiang T., Sim T., Karanewsky D., Gu X.-J., Zhou V., Liu Y., Ohmori O., Caldwell J., Gray N., and He Y. Bioorg. Med. Chem. Lett. 16 (2006) 2173
10. Choi H.-S., Wang Z., Richmond W., He X., Yang K., Jiang T., Karanewsky D., Gu X.-J., Zhou V., Liu Y., Che J., Lee C.C., Caldwell J., Kanazawa T., Umemura I., Matsuura N., Ohmori O., Honda T., Gray N., and He Y. Bioorg. Med. Chem. Lett. 16 (2006) 2689
11. Detailed description of the enzyme assays: Gerspacher, M.; Furet, P.; Vangrevelinghe, E. PCT Int. Appl. WO2008031594, 2008; Chem. Abstr. 2008, 148, 379605.
12. 50 values.
13. +. A structurally closely related compound was used as analytical internal standard. Quantification of blood levels of the parent compound was based on a seven-level calibration curve (in triplicate) using blank rat blood samples spiked with stock solutions of external and internal standards. Pharmacokinetic parameters were estimated using a non-compartmental approach. AUCs iv and po were calculated using the trapezoidal rule, then extrapolated to infinity using the terminal half-life calculated by log-linear regression from the last three (measurable) blood levels after iv administration.